

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) (E)-2-(5-Chlorothien-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide in substantially crystalline form having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1-9.2 (± 0.1), 16.0-16.1 (± 0.1), 18.0-18.2 (± 0.1), and 18.3-18.4 (± 0.1) degrees.
2. (Original) The substantially crystalline form as claimed in claim 1 in the form of needle-shaped crystals.
3. (Original) The substantially crystalline form as claimed in claim 1 in the form of lath-shaped crystals.
4. (Original) The substantially crystalline form as claimed in claim 1 in the form of a mixture of needle-shaped and lath-shaped crystals.
5. (Previously Presented) The substantially crystalline form as claimed in claim 1 wherein the melting point is greater than 160°C.
6. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at two or more positions selected from the group consisting of 9.1-9.2 (± 0.1), 16.0-16.1 (± 0.1), 18.0-18.2 (± 0.1), and 18.3-18.4 (± 0.1) degrees.

7. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at three or more positions selected from the group consisting of 9.1-9.2 (± 0.1), 16.0-16.1 (± 0.1), 18.0-18.2 (± 0.1), and 18.3-18.4 (± 0.1) degrees.
8. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at all four positions selected from the group consisting of 9.1-9.2 (± 0.1), 16.0-16.1 (± 0.1), 18.0-18.2 (± 0.1), and 18.3-18.4 (± 0.1) degrees.
9. (Canceled).
10. (Canceled).
11. (Canceled).
12. (Canceled).
13. (Previously Presented) A method for the preparation of (E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide in substantially crystalline form which method comprises crystallisation of (E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide from an organic solution, optionally in the presence of water.
14. (Original) A method as claimed in claim 13 wherein the organic solution selected from: an aromatic hydrocarbon, a cycloalkane, an ester, an alcohol or a ketone, or a mixture thereof.
15. (Cancelled).
16. (Cancelled).

17. (Cancelled).

18. (Cancelled).

19. (New). The substantially crystalline form as claimed in claim 1, wherein substantially crystalline form is meant substantially free of an amorphous form of (E)-2-(5-Chlorothien-2-yl)-N-{{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide.